DCM
CRNX icon

Dupont Capital Management’s Crinetics Pharmaceuticals CRNX Stock Holding History

Dupont Capital Management’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-8,629
Closed -$161K – 1567
2022
Q2 		$161K Buy
8,629
+2,297
+36% +$45.8K 0.01% 1037
2022
Q1 		$139K Sell
6,332
-561
-8% -$11.4K 0.01% 1195
2021
Q4 		$196K Buy
+6,893
New +$170K 0.01% 1117

Other funds holding CRNX

DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Dupont Capital Management's CRNX Position: Q3 2022 in Review

Dupont Capital Management sold out of Crinetics Pharmaceuticals (CRNX) in Q3 2022, closing a stake of 8,629 shares — an estimated $161K sold.

Dupont Capital Management first reported a position in CRNX in Q4 2021 and held it in 3 quarters. The position peaked at $196K in Q4 2021. 122 funds tracked by Wall St. Rank hold CRNX as of Q3 2022.

  • Dupont Capital Management reported no remaining Crinetics Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
  • Dupont Capital Management sold 8,629 Crinetics Pharmaceuticals shares in Q3 2022, an estimated $161K.
  • Dupont Capital Management first reported a position in Crinetics Pharmaceuticals in Q4 2021 and held it in 3 quarters.
  • Dupont Capital Management's Crinetics Pharmaceuticals position peaked at $196K in Q4 2021.
  • 122 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q3 2022.

Based on Dupont Capital Management's 13F filing for Q3 2022, filed 31 Oct 2022.